<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071512</url>
  </required_header>
  <id_info>
    <org_study_id>10-094A</org_study_id>
    <nct_id>NCT01071512</nct_id>
  </id_info>
  <brief_title>Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis</brief_title>
  <official_title>Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-term objective is to further establish the role of Tysabri in preventing
      neurological degeneration in multiple sclerosis (MS) and to establish powerful and efficient
      new markers for neurological degeneration in MS. The study intends to correlate cognition
      with two instruments and their measurements-MRI and OCT (optical coherence tomography).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims are:

        1. To determine the effects of Tysabri on cognition (memory, thought processes, etc.)

        2. To determine the effects of Tysabri on specific MRI markers for cognitive dysfunction

        3. To determine the effects of Tysabri on retinal nerve fiber layer thickness (RNFL) using
           optical coherence tomography (OCT), a special instrument used in ophthalmology
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cognitive Function Over Time</measure>
    <time_frame>Baseline, 48 weeks, 96 weeks</time_frame>
    <description>Cognitive function was assessed using the oral version of the Symbol Digit Modalities Test (SDMT). The number of correct responses in 90 seconds was recorded (possible range 0-110). For analysis, SDMT scores were converted to z-scores using published age and education based norms. A negative z-score indicates a SDMT score below the mean based on the age and education based norms, for example a z-score of -2 = 2 standard deviations below the mean; a positive z-score indicating a score above the mean. Higher scores indicate better cognitive function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in Retinal Nerve Fiber Layer Thickness</measure>
    <time_frame>Baseline, 24, 48, 72, and 96 weeks</time_frame>
    <description>Retinal Nerve Fiber Layer (RNFL) thickness was measured using spectral domain OCT scans by a trained technician. Scans were performed without pupil dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in Brain Parenchymal Fraction</measure>
    <time_frame>Baseline, 48 weeks, 96 weeks</time_frame>
    <description>Measured based on MRI scan on a 3T Phillips scanner. This is a measure of brain atrophy (i.e., brain volume loss) with lower values indicating greater atrophy (possible range 0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in Normalized Thalamic Volume</measure>
    <time_frame>Baseline, 48 weeks, 96 weeks</time_frame>
    <description>Measured on MRI scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in Normalized Hippocampal Volume</measure>
    <time_frame>Baseline, 48 weeks, 96 weeks</time_frame>
    <description>Measured on MRI scan</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Tysabri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natalizumab 300 mg IV every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tysabri</intervention_name>
    <description>Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.</description>
    <arm_group_label>Tysabri</arm_group_label>
    <other_name>Natalizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 through 60 years of age inclusive

          -  Diagnosis of relapsing remitting multiple sclerosis

          -  Prior to treatment phase, have had disease activity with at least 1 documented relapse
             during the previous year OR 2 documented relapses during the previous 2 years OR one
             or more new MRI lesions (Gd+ and/or T2 hyperintense)

          -  An Expanded Disability Status Scale (EDSS) score of 0-4.5 inclusive

          -  Neurologically stable with no evidence of relapse or corticosteroid treatment within
             30 days prior to treatment

          -  Never been treated with Tysabri/natalizumab.

        Exclusion Criteria:

          -  Another type of MS other than relapsing remitting multiple sclerosis (RRMS)

          -  A history of chronic disease of the immune system other than MS or a known
             immunodeficiency syndrome/immunocompromised

          -  A history or presence of cancer (except for successfully treated basal or squamous
             cell carcinoma of skin)

          -  Active systemic bacterial, viral or fungal infections, or diagnosis of AIDS, Hepatitis
             B, Hepatitis C infection defined as a positive HIV antibody, Hepatitis B surface
             antigen or Hepatitis C antibody tests, respectively

          -  Have received any live or live attenuated vaccines (including for varicella-zoster
             virus or Measles) within the last 2 months

          -  Have received total lymphoid irradiation or bone marrow transplantation

          -  Have been treated with: corticosteroids or adrenocorticotropic hormones (ACTH) within
             the last month, IFN-β or glatiramer acetate within the last 3 months,
             immunosuppressive medications such as azathioprine or methotrexate within the last 6
             months, immunoglobulins and/or monoclonal antibodies (including natalizumab) within
             the last 6 months, or cladribine, cyclophosphamide or mitoxantrone at any time.

          -  Any medically unstable condition or a progressive neurological disorder, other than
             MS, which may affect participation in the study

          -  History of any clinically significant cardiac, endocrinologic, hematologic, hepatic,
             immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,
             renal or other major disease

          -  Unable to undergo MRI scans, including claustrophobia, have a pacemaker or history of
             hypersensitivity to gadolinium-DTPA

          -  Have had a relapse within 30 days prior AND/OR not stabilized from a previous relapse

          -  History of severe allergic or anaphylactic reactions or known drug hypersensitivity to
             natalizumab/Tysabri

          -  A clinically significant infectious disease, such as cellulitis, pneumonia, septicemia

          -  History of progressive multifocal leukoencephalopathy(PML)

          -  Participation in any clinical research study evaluating another investigational drug
             or therapy within the last 6 months

          -  History of Tysabri therapy

          -  Abnormal screening blood test

          -  Females who are not postmenopausal for at least 1 year, surgically sterile or willing
             to practice effective contraception during the study

          -  Nursing mothers, pregnant women, and women planning to become pregnant while on study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Bernard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <results_first_submitted>June 15, 2017</results_first_submitted>
  <results_first_submitted_qc>August 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2017</results_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>OCT</keyword>
  <keyword>Tysabri</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tysabri</title>
          <description>Natalizumab 300 mg IV every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Development of antibodies to drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>positive anti-JC virus antibody test</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes patients that completed treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Tysabri</title>
          <description>Natalizumab 300 mg IV every 4 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cognitive Function Over Time</title>
        <description>Cognitive function was assessed using the oral version of the Symbol Digit Modalities Test (SDMT). The number of correct responses in 90 seconds was recorded (possible range 0-110). For analysis, SDMT scores were converted to z-scores using published age and education based norms. A negative z-score indicates a SDMT score below the mean based on the age and education based norms, for example a z-score of -2 = 2 standard deviations below the mean; a positive z-score indicating a score above the mean. Higher scores indicate better cognitive function.</description>
        <time_frame>Baseline, 48 weeks, 96 weeks</time_frame>
        <population>Summary statistics are based on the 15 subjects who completed treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tysabri</title>
            <description>Natalizumab 300 mg IV every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Function Over Time</title>
          <description>Cognitive function was assessed using the oral version of the Symbol Digit Modalities Test (SDMT). The number of correct responses in 90 seconds was recorded (possible range 0-110). For analysis, SDMT scores were converted to z-scores using published age and education based norms. A negative z-score indicates a SDMT score below the mean based on the age and education based norms, for example a z-score of -2 = 2 standard deviations below the mean; a positive z-score indicating a score above the mean. Higher scores indicate better cognitive function.</description>
          <population>Summary statistics are based on the 15 subjects who completed treatment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis used all available data from subjects, including those who dropped out early.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Over Time in Retinal Nerve Fiber Layer Thickness</title>
        <description>Retinal Nerve Fiber Layer (RNFL) thickness was measured using spectral domain OCT scans by a trained technician. Scans were performed without pupil dilation.</description>
        <time_frame>Baseline, 24, 48, 72, and 96 weeks</time_frame>
        <population>Summary statistics are provided based on subjects completing all treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tysabri</title>
            <description>Natalizumab 300 mg IV every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change Over Time in Retinal Nerve Fiber Layer Thickness</title>
          <description>Retinal Nerve Fiber Layer (RNFL) thickness was measured using spectral domain OCT scans by a trained technician. Scans were performed without pupil dilation.</description>
          <population>Summary statistics are provided based on subjects completing all treatment</population>
          <units>micrometer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis used all available data</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Over Time in Brain Parenchymal Fraction</title>
        <description>Measured based on MRI scan on a 3T Phillips scanner. This is a measure of brain atrophy (i.e., brain volume loss) with lower values indicating greater atrophy (possible range 0-1).</description>
        <time_frame>Baseline, 48 weeks, 96 weeks</time_frame>
        <population>Summary statistics are based on subjects completing treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tysabri</title>
            <description>Natalizumab 300 mg IV every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change Over Time in Brain Parenchymal Fraction</title>
          <description>Measured based on MRI scan on a 3T Phillips scanner. This is a measure of brain atrophy (i.e., brain volume loss) with lower values indicating greater atrophy (possible range 0-1).</description>
          <population>Summary statistics are based on subjects completing treatment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.969" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.971" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis used all available data</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Over Time in Normalized Thalamic Volume</title>
        <description>Measured on MRI scan</description>
        <time_frame>Baseline, 48 weeks, 96 weeks</time_frame>
        <population>Summary statistics are based on subjects completing all treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tysabri</title>
            <description>Natalizumab 300 mg IV every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change Over Time in Normalized Thalamic Volume</title>
          <description>Measured on MRI scan</description>
          <population>Summary statistics are based on subjects completing all treatment</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis used all available data</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Over Time in Normalized Hippocampal Volume</title>
        <description>Measured on MRI scan</description>
        <time_frame>Baseline, 48 weeks, 96 weeks</time_frame>
        <population>Summary statistics are based on subjects completing all treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tysabri</title>
            <description>Natalizumab 300 mg IV every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change Over Time in Normalized Hippocampal Volume</title>
          <description>Measured on MRI scan</description>
          <population>Summary statistics are based on subjects completing all treatment</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis used all available data</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>96 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tysabri</title>
          <description>Natalizumab 300 mg IV every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adil Javed</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773.834.0558</phone>
      <email>ajaved@neurology.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

